Forest gets option to buy moksha8 as Watson sells stake
This article was originally published in Scrip
Executive Summary
Forest Laboratories has entered into a strategic deal with the Latin American-focused product commercialisation company moksha8 which gives it an option to buy the firm outright in two years' time. It will provide up to $125 million to moksha8 over two years and has granted it exclusive rights to sell in Latin America the antidepressant Viibryd (vilazodone), one of the newer products that Forest is pinning its future hopes on.
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Sanofi’s Latest Credit Facility Offers Win-Win Model For Pharma And Society
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Need a specific report? 1000+ reports available
Buy Reports